Article
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms.
Antiviral research - 1 Jun 2014
Boglione Lucio, Cusato Jessica, De Nicolò Amedeo, Cariti Giuseppe, Allegra Sarah, Ghisetti Valeria, Di Perri Giovanni, D'Avolio Antonio
Abstract excerpt
BACKGROUND: The current treatment of HCV-4 patients is dual therapy with PEG-IFN and ribavirin; however, new drugs against this genotype will be available within few months. Despite the evidenced good virological response in IFN-free regimens, the high cost of these new therapies will require patient selection. In our paper we propose the use of both rs8099917 and rs12979860 IL28-B polymorphisms, in order to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.